FederalOpenFixed dateNational Institutes of Health

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Award ceiling: Not stated
Closes: Nov 19, 2026
Last verified: 2026-09-04

Per-recipient award not stated for city or township governments, county governments, for profit organizations other than small businesses, independent school districts, native american tribal governments (federally recognized), native american tribal organizations (other than federally recognized tribal governments), nonprofits having a 501(c)(3) status with the irs, other than institutions of higher education, nonprofits that do not have a 501(c)(3) status with the irs, other than institutions of higher education, others (see text field entitled "additional information on eligibility" for clarification), private institutions of higher education, public and state controlled institutions of higher education, public housing authorities/indian housing authorities, small businesses, special district governments, state governments, closing Nov 19, 2026.

Official page Sign in to trackVerified2026-09-04

City or township governmentsCounty governmentsFor profit organizations other than small businessesIndependent school districtsNative American tribal governments (Federally recognized)Native American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)Private institutions of higher educationPublic and State controlled institutions of higher educationPublic housing authorities/Indian housing authoritiesSmall businessesSpecial district governmentsState governmentsHealth & Human Services

In one sentence

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) does not state a per-recipient award amount, open to city or township governments, county…

Record fields

Program pool (total): Not confirmed
Total across all awards in this programme. Not an amount any single applicant can receive.
Award ceiling (per project): Not confirmed
Award floor: Not confirmed
Typical award: Not confirmed
Deadline: Nov 19, 2026
Deadline type: Fixed date
Opens: Nov 22, 2024
Status: Open
Eligible entities: City or township governments · County governments · For profit organizations other than small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Small businesses · Special district governments · State governments
Geography: Not stated
Matching funds: Not confirmed
Disbursement: Not confirmed
Application effort: Not confirmed
Use of funds: phase 1 clinical trials · phase 1b/phase 2a clinical trials · evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD)
Currency: USD

How much money is available?

Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.

Program pool (total)Across all awards this cycle

Not stated

Award ceiling (per project)The most one applicant can receive

Not stated

Who can apply?

level

federal

Derived from the source that published this record

entity

City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education

+5more

, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governments

Source field: entity types

industry

Health & Human Services

Source field: industries

demographic

Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs)

+1more

, U.S. Territory or Possession

Source field: demographics

use

evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD), phase 1 clinical trials, phase 1b/phase 2a clinical trials

Source field: use of funds

size limit

Not confirmed

Source field: applicant size limit

clause text

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.

When does it close?

Nov 19, 202673 daysDeadline type Fixed date

What can the money be used for?

3 categorysThe source’s own spending categories, and what is not parsed.

phase 1 clinical trialsphase 1b/phase 2a clinical trialsevaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD)

These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.

What comparable notices state

333 recordsStated ceilings on open records in the same industry.

Among open records stored under Health & Human Services, 333 of 928 state an award ceiling. Those that do run:

25th percentile$250,000
Median$500,000
75th percentile$1,200,000

A statistical estimate, not a prediction. It describes what a set of notices has published in this catalogue on the day you read it, and says nothing about what this programme will award. Records stating no ceiling are excluded rather than counted as zero, and the programme pool — what a funder has across every applicant — is a different column and is never mixed in.

Common questions

3 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.

When is the application deadline?: Nov 19, 2026.
Who is eligible to apply?: City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governments.
What can the funding be used for?: phase 1 clinical trials, phase 1b/phase 2a clinical trials, evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD), as classified by the source.

AI summary of the source text

Optional. Every core field on this record is already above, free and complete.

AI summary of the source text

Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.

Included with Studio

Provenance

Source pagegrants.gov

Retrieved2026-09-04

MethodAutomated check

First seen2026-09-03

The official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.